Revealed a team of researchers and scientists at the University of California - San Francisco, USA for new information and very exciting about the discovery of a new drugs for the treatment of diabetes type I, which affects children in most of the number of infected more than 35 million people.
And knows the new drug as "teplizumab", which is still in the process of laboratory experiments, has proved very effective in reducing the severity of the disease and stop the development of diabetes type I in the early stages, especially for patients who suffer from altitude medium in the level of glucose in blood, and they need to a large number of units of the hormone insulin.
The researchers stressed that this property showed the effectiveness of large at more than 50% of people who were subjected to the study, totaling 52 people, during the second phase of clinical trials, where he managed property "teplizumab" to stimulate the secretion of insulin on a regular basis during this period and for a period exceeding for two years, which has led to control of blood glucose levels and limited the symptoms of the disease.
The mechanism of action of drug dependent "teplizumab" to control autoimmune reactions, which uses antibodies directed against one of the vehicles in the immune T-cells and is known as "CD3", and prevents them from attacking the beta cells in the pancreas, which secretes the hormone insulin.
The researchers said the study compilers they are very fascinated with the results shown by this property and large , where he was able to improve the condition dramatically by confirmation of a lot of patients who use it.
The findings in a recent study published in the journal "Diabetes", and on the website of the journal in the seventh month of August.
No comments:
Post a Comment